Emergent BioSolutions (EBS) Interest Coverage Ratio Growth (1y) (2012 - 2026)
Emergent BioSolutions (EBS) Interest Coverage Ratio Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -83.16% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 128.45% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -97.39% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -8.29% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -11,593.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11,593.56% |
| Mar 31, 2026 | -73.18% |
| Dec 31, 2025 | -55.83% |
| Sep 30, 2025 | -35.24% |
| Jun 30, 2025 | 100.53% |
| Mar 31, 2025 | 82.43% |
| Dec 31, 2024 | 39.66% |
| Sep 30, 2024 | 163.23% |
| Jun 30, 2024 | 15.80% |
| Mar 31, 2024 | 123.97% |
| Dec 31, 2023 | 61.31% |
| Sep 30, 2023 | -130.59% |
| Jun 30, 2023 | -4.69% |
| Mar 31, 2023 | -1,258.70% |
| Dec 31, 2022 | -113.10% |
| Sep 30, 2022 | -0.15% |
| Jun 30, 2022 | -1,284.87% |
| Mar 31, 2022 | -92.07% |
| Dec 31, 2021 | 34.27% |
| Sep 30, 2021 | -165.98% |